Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237134 | 0.80 | BCHE (0.47) | ALDH1A1SMN1; SMN2LMNAALOX15BCHE | |
| SCHEMBL19089524 | 0.78 | HTT (0.48) | ALDH1A1SMN1; SMN2LMNAALOX15BCHE | |
| SCHEMBL9965045 | 0.78 | BCHE (0.49) | ALDH1A1SMN1; SMN2LMNAALOX15BCHE | |
| SCHEMBL256103 | 0.77 | — | — | |
| SCHEMBL22245536 | 0.77 | BCHE (0.45) | ALDH1A1SMN1; SMN2LMNAALOX15BCHE | |
| SCHEMBL13090080 | 0.76 | BCHE (0.44) | ALDH1A1SMN1; SMN2LMNAALOX15BCHE | |
| SCHEMBL3304141 | 0.74 | HTT (0.45) | ALDH1A1SMN1; SMN2LMNAALOX15BCHE | |
| SCHEMBL2755869 | 0.74 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2LMNAALOX15BCHE | |
| SCHEMBL19659449 | 0.73 | GLS (0.35) | ALDH1A1SMN1; SMN2LMNAALOX15 | |
| SCHEMBL8240047 | 0.73 | KDM4E (0.39) | ALDH1A1SMN1; SMN2LMNAALOX15BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3290415-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | Trevena, Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| CN-101460453-B | Novel sulfonamide compounds | ACTELION PHARMACEUTICALS LTD | 2012-10-03 | — | — | CN | disclosed |
| US-8003654-B2 | N-glycinsulfonamide derivatives and uses as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-23 | — | — | US | disclosed |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20090275588-A1 | NOVEL SULFONAMIDE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-11-05 | — | — | US | disclosed |
| CN-101460453-A | Novel sulfonamide compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-17 | — | — | CN | disclosed |
| EP-2007717-A1 | NOVEL SULFONAMIDE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007116374-A1 | NOVEL SULFONAMIDE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, RUNX1, ACIN1 | ALDH1A1 256/4885SMN1; SMN2 574/4885LMNA 1738/4885 |
| US-20090275588-A1 | NOVEL SULFONAMIDE COMPOUNDS | HCRTR2, HCRTR1, NPSR1 | ALDH1A1 2824/4885SMN1; SMN2 1760/4885LMNA 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.